Related Experiment Video

Updated: Jun 21, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression

M E Montañez-Wiscovich1, D D Seachrist, M D Landis

  • 1Department of Pharmacology, Case Western Reserve University, Cleveland, OH 44106-4965, USA.

Oncogene
|August 4, 2009
PubMed

Insights

LIM-only protein 4 (LMO4) drives proliferation in ErbB2-positive breast cancer by regulating cell cycle and cullin-3. LMO4 is a novel target for treating this aggressive disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • ErbB2/HER2/Neu-overexpressing breast cancers exhibit poor survival due to rapid proliferation and metastasis.
  • Identifying downstream targets of ErbB2 is crucial for developing effective therapies for this aggressive cancer subtype.

Purpose of the Study:

  • To investigate LIM-only protein 4 (LMO4) as a downstream target of ErbB2 and PI3K in breast cancer.
  • To elucidate the role of LMO4 in mediating ErbB2-induced proliferation and cell cycle regulation.

Main Methods:

  • Gene expression profiling to identify upregulated genes in ErbB2-induced tumorigenesis.
  • LMO4 silencing experiments in ErbB2-dependent breast cancer cells.
  • Cell cycle analysis and assessment of cell cycle regulatory proteins (e.g., cullin-3, Cyclin D1, Cyclin E).

Main Results:

  • LMO4 is confirmed as a downstream target of ErbB2 and PI3K in relevant breast cancer cells.
  • LMO4 silencing reduced proliferation and induced G2/M arrest, linked to decreased cullin-3 levels.
  • LMO4 expression oscillates with the cell cycle, preceding cullin-3 oscillations, and is elevated in high-grade breast cancers.

Conclusions:

  • LMO4 is a novel cell cycle regulator that plays a critical role in ErbB2-induced proliferation.
  • LMO4 represents a potential therapeutic target for ErbB2-positive breast cancers.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...